The global healthcare industry has entered an era where innovation is not just about profit — it’s about purpose. Nowhere is this more evident than in the rare disease drugs market, a sector dedicated to addressing the unmet medical needs of millions of patients suffering from conditions that affect only a small fraction of the population. Despite their rarity, these diseases...

The global rare disease drugs market is witnessing remarkable expansion fueled by advances in precision medicine, biotechnology innovation, and strong regulatory backing. In 2025, the market is valued at around USD 217.93 billion and is projected to exceed USD 587 billion by 2034, marking an impressive compound annual growth rate (CAGR) of 11.64%.​ Get Report Link...